Sublingual Atropine Bioequivalence by Route of Administration (SABER)
Status:
COMPLETED
Trial end date:
2024-05-22
Target enrollment:
Participant gender:
Summary
A randomized, two-period, two-sequence, crossover study to assess the bioequivalence, bioavailability, and pharmacokinetics (PK) of a single dose of atropine administered sublingually (SL) or intramuscularly (IM) in healthy adult volunteers.
Phase:
PHASE1
Details
Lead Sponsor:
Biomedical Advanced Research and Development Authority
Collaborators:
Allucent Government Services (US), LLC Rho Federal Systems Division, Inc.